Pfizer’S ELREXFIO Outperforms Standard Regimens And Meets Primary Endpoint In Phase 3 Study In Relapsed Or Refractory Multiple Myeloma

Oct 27 (Reuters) - Pfizer Inc. PFE.N:

• PFIZER’S ELREXFIO OUTPERFORMS STANDARD REGIMENS AND MEETS PRIMARY ENDPOINT IN PHASE 3 STUDY IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA

• PFIZER - ELREXFIO SHOWS STATISTICALLY SIGNIFICANT BENEFIT WITH MEDIAN PFS NOT YET REACHED IN RRMM

• PFIZER - ELREXFIO MEETS PRIMARY ENDPOINT IN PHASE 3 MAGNETISMM-32 STUDY FOR RRMM

• PFIZER - OVER 75% OF ELREXFIO PATIENTS PROGRESSION-FREE; ESTIMATED 68% PFS AT 18 MONTHS

• PFIZER - GRADE 3+ INFECTIONS IN 27.5% ELREXFIO PATIENTS VERSUS 18.1% INVESTIGATOR'S CHOICE; GRADE 5: 0.8% VERSUS 1.6%

• PFIZER - PLANS GLOBAL HEALTH AUTHORITY SUBMISSIONS AND FUTURE PUBLICATION OF MAGNETISMM-32 RESULTS

• PFIZER: SAFETY PROFILE OF ELREXFIO IN MAGNETISMM-32 WAS CONSISTENT WITH ITS KNOWN PROFILE

Further company coverage: PFE.N